SB357 - Gabe Griffin Right to Try Act

• Authorizes terminally ill patients who have exhausted FDA-approved treatment options to access and use investigational drugs, biological products, or devices that have completed phase 1 clinical trials but are not yet approved for general use.

• Requires eligible patients to obtain written informed consent that discloses potential risks, outcomes, costs, and liability, signed by the patient (or parent/guardian if minor) and attested to by their physician and a witness.

• Prohibits licensing boards and disciplinary bodies from sanctioning health care providers solely for recommending or providing experimental treatments under the act, and prevents state officials from blocking patient access to investigational treatments.

• Clarifies that manufacturers are not required to provide treatments; health insurers, governmental agencies, and hospitals are not required to cover costs or provide services related to experimental treatments; and patients or their estates bear financial liability unless contracted otherwise.

• Limits private causes of action against manufacturers and health care providers for harm from investigational treatments if they comply in good faith with the act's terms, except in cases of failure to exercise reasonable care.